Exome Asset Management LLC — 13F Holdings & Portfolio

CIK 2011932 · latest 13F-HR filed 2026-08-14

Exome Asset Management LLC manages $162.1M in 13F-reported U.S. long-equity assets across 52 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are GH (6.25%), PRAX (5.62%), TGTX (5.59%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 15 new positions, exited 8, added to 9, and trimmed 24.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Filer Information
Address
330 MADISON AVENUE
NEW YORK, NY 10017
Phone
(212) 403-3900
Filing Manager
Exome Asset Management LLC
NEW YORK, NY
Signatory
BRIANNE SHERGILL
Chief Compliance Officer
Loading holdings…
AUM

$162.1M

Long-equity book

Holdings

52

Distinct positions

Period

2026-06-30

Filed 2026-08-14

Q/Q Activity

+15 / −8 / ↑9 / ↓24

vs 2026-03-31

Firm Profile & Key People
Name Title / Status Ownership Type

Top Adds (vs prior quarter)

  • GUARDANT HEALTH INC$2.5M +32.5%
  • LIQUIDIA CORPORATION$1.4M +80.9%
  • MAZE THERAPEUTICS INC$780.4K +29.5%
  • 10X GENOMICS INC$661.3K +20.2%
  • GLAUKOS CORP$528.6K +23.5%
Show all 9

Top Trims

  • PRAXIS PRECISION MEDICINES I-$5.5M -37.8%
  • BRIDGEBIO PHARMA INC-$3.6M -72.7%
  • ENLIVEN THERAPEUTICS INC-$3.5M -41.1%
  • INSMED INC-$2.9M -66.1%
  • COGENT BIOSCIENCES INC-$2.6M -24.0%
Show all 24

New Positions

  • TG THERAPEUTICS INC$9.1M
  • ABIVAX SA$6.2M
  • UNIQURE NV$3.7M
  • ASTRAZENECA PLC$2.3M
  • VIKING THERAPEUTICS INC$1.9M
Show all 15

Exited Positions

  • ELEVANCE HEALTH INC FORMERLY$4.3M
  • APELLIS PHARMACEUTICALS INC$3.4M
  • AVALO THERAPEUTICS INC$2.4M
  • SOLENO THERAPEUTICS INC$2.1M
  • 4D MOLECULAR THERAPEUTICS IN$1.2M
Show all 8
All Holdings

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 GUARDANT HEALTH INC GH 40131M109 $10.1M 6.25% 67,500 SH
2 PRAXIS PRECISION MEDICINES I PRAX 74006W207 $9.1M 5.62% 27,205 SH
3 TG THERAPEUTICS INC TGTX 88322Q108 $9.1M 5.59% 164,915 SH
4 COGENT BIOSCIENCES INC COGT 19240Q201 $8.1M 5.03% 210,523 SH
5 IONIS PHARMACEUTICALS INC IONS 462222100 $7.0M 4.31% 88,177 SH
6 ELI LILLY & CO LLY 532457108 $6.6M 4.06% 5,492 SH
7 ABIVAX SA ABVX 00370M103 $6.2M 3.85% 46,878 SH
8 ALUMIS INC ALMS 022307102 $5.8M 3.55% 204,418 SH
9 CYTOKINETICS INC CYTK 23282W605 $5.1M 3.16% 60,056 SH
10 ENLIVEN THERAPEUTICS INC ELVN 29337E102 $5.1M 3.14% 100,203 SH
11 VERA THERAPEUTICS INC VERA 92337R101 $4.2M 2.57% 97,276 SH
12 UNITEDHEALTH GROUP INC UNH 91324P102 $4.0M 2.46% 9,612 SH
13 10X GENOMICS INC TXG 88025U109 $3.9M 2.43% 102,629 SH
14 NATERA INC NTRA 632307104 $3.7M 2.31% 13,800 SH
15 UNIQURE NV QURE N90064101 $3.7M 2.30% 81,056 SH
16 RHYTHM PHARMACEUTICALS INC RYTM 76243J105 $3.6M 2.21% 32,209 SH
17 MAZE THERAPEUTICS INC MAZE 578784100 $3.4M 2.11% 114,692 SH
18 MONTE ROSA THERAPEUTICS INC GLUE 61225M102 $3.3M 2.05% 137,115 SH
19 MOONLAKE IMMUNOTHERAPEUTICS MLTX 61559X104 $3.2M 2.00% 166,493 SH
20 ALKERMES PLC ALKS G01767105 $3.2M 1.98% 61,336 SH
21 LIQUIDIA CORPORATION LQDA 53635D202 $3.1M 1.93% 39,224 SH
22 UNITED THERAPEUTICS CORP DEL UTHR 91307C102 $2.9M 1.81% 5,410 SH
23 GLAUKOS CORP GKOS 377322102 $2.8M 1.71% 19,862 SH
24 ARROWHEAD PHARMACEUTICALS IN ARWR 04280A100 $2.6M 1.62% 32,214 SH
25 AGIOS PHARMACEUTICALS INC AGIO 00847X104 $2.6M 1.61% 70,500 SH
26 CRESCENT BIOPHARMA INC. CBIO G2545C104 $2.3M 1.42% 127,769 SH
27 ASTRAZENECA PLC AZN G0593M107 $2.3M 1.39% 12,045 SH
28 BOSTON SCIENTIFIC CORP BSX 101137107 $2.1M 1.27% 48,347 SH
29 ADAGENE INC ADAG 005329107 $2.1M 1.27% 488,293 SH
30 PENUMBRA INC PEN 70975L107 $2.0M 1.23% 6,300 SH
31 INTUITIVE SURGICAL INC ISRG 46120E602 $2.0M 1.20% 4,908 SH
32 VIKING THERAPEUTICS INC VKTX 92686J106 $1.9M 1.15% 47,861 SH
33 OCULAR THERAPEUTIX INC OCUL 67576A100 $1.8M 1.10% 181,588 SH
34 EQUILLIUM INC EQ 29446K106 $1.8M 1.09% 552,956 SH
35 ASCENDIS PHARMA A/S ASND K08588103 $1.8M 1.08% 6,573 SH
36 CORBUS PHARMACEUTICALS HLDGS CRBP 21833P301 $1.7M 1.07% 184,914 SH
37 CYTOMX THERAPEUTICS INC. CTMX 23284F105 $1.7M 1.06% 460,067 SH
38 VERASTEM INC VSTM 92337C203 $1.6M 1.01% 429,041 SH
39 NEKTAR THERAPEUTICS NKTR 640268306 $1.6M 0.97% 22,417 SH
40 CLEARPOINT NEURO INC CLPT 18507C103 $1.5M 0.92% 83,636 SH
41 INSMED INC INSM 457669307 $1.5M 0.91% 13,873 SH
42 CARIS LIFE SCIENCES INC CAI 142152107 $1.4M 0.86% 78,180 SH
43 BRIDGEBIO PHARMA INC BBIO 10806X102 $1.4M 0.84% 18,359 SH
44 ZENAS BIOPHARMA INC ZBIO 98937L105 $1.3M 0.82% 52,443 SH
45 NOVABRIDGE BIOSCIENCES NBP 44975P103 $1.1M 0.69% 576,960 SH
46 ESTABLISHMENT LABS HLDGS INC ESTA G31249108 $1.1M 0.69% 13,100 SH
47 RELAY THERAPEUTICS INC RLAY 75943R102 $889.3K 0.55% 47,531 SH
48 GERON CORP GERN 374163103 $798.8K 0.49% 624,046 SH
49 BRIGHT MINDS BIOSCIENCES INC DRUG 10919W405 $709.7K 0.44% 10,110 SH
50 COMPASS THERAPEUTICS INC CMPX 20454B104 $604.8K 0.37% 276,165 SH
Filing History
Period Filed AUM Holdings Accession
2026-06-30 2026-08-14 $162.1M 52 0001420506-26-001714
2026-03-31 2026-05-15 $193.3M 56 0001420506-26-001033
2025-12-31 2026-02-13 $209.1M 60 0001420506-26-000376
2025-09-30 2025-11-14 $165.1M 68 0001420506-25-003369